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Efficiency of Exome Sequencing for the Molecular
Diagnosis of Pseudoxanthoma Elasticum
Mohammad J. Hosen1,2, Filip Van Nieuwerburgh3, Wouter Steyaert1, Dieter Deforce3, Ludovic Martin4,
Georges Leftheriotis5, Anne De Paepe1, Paul J. Coucke1,6 and Olivier M. Vanakker1,6
The molecular etiology of pseudoxanthoma elasticum (PXE), an autosomal recessive connective tissue disorder,
has become increasingly complex as not only mutations in ATP-binding cassette family C member 6 (ABCC6) but
also ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) and gamma-glutamyl carboxylase (GGCX) can
cause resembling phenotypes. Identification of modifier genes, such as vascular endothelial growth factor A, has
further contributed to the molecular heterogeneity of PXE. In such heterogeneous diseases, next-generation
sequencing (NGS) allows to perform mutation screening of several genes in a single reaction. We explored
whole-exome sequencing (WES) as an efficient diagnostic tool to identify the causal mutations in ABCC6, GGCX,
ENPP1, and vitamin K epoxide reductase complex, subunit 1 (VKORC1) in 16 PXE patients. WES identified a causal
ABCC6 mutation in 30 out of 32 alleles and one GGCX mutation, whereas no causal mutations in ENPP1 or
VKORC1 were detected. Exomes with insufficient reads (p20 depth) for the four genes and patients with single
mutations were further evaluated by Sanger sequencing (SS), but no additional mutations were found. The
potential of WES compared with targeted NGS is the ease to examine target genes and the opportunity to search
for novel genes when targeted analysis is negative. Together with low cost, rapid and less laborious workflow, we
conclude that WES complemented with SS can provide a tiered approach to molecular diagnostics of PXE.
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INTRODUCTION
Pseudoxanthoma elasticum (PXE; OMIM#264800) is an auto-
somal recessive connective tissue disorder, characterized by
ectopic mineralization of elastic fibers in the extracellular
matrix of the skin, eyes, and the cardiovascular system. The
prevalence of PXE is estimated to be around 1 in 50,000 with
a carrier frequency ofB1:150–300 (Uitto et al., 2011). PXE is
caused by mutations in the ABCC6 gene, which encodes a
putative efflux transporter, ATP-binding cassette family C
member 6 (ABCC6), primarily expressed in liver and kidney,
and mediates ATP release from the liver (Jansen et al., 2014).
Over 1000 mutant alleles have been identified in patients with
PXE from varied ancestral and ethnic backgrounds (Chassaing
et al., 2005; Miksch et al., 2005; Pfendner et al., 2007).
Besides the presence of two pseudogenes (ABCC6-c1 and
ABCC6-c2) containing sequences highly homologous to the
50-end of ABCC6, the molecular diagnosis of PXE is becoming
increasingly challenging as the molecular etiology of the
disease becomes more complex (Pulkkinen et al., 2001).
Indeed, PXE-related disorders such as PXE-like disease with
coagulation deficiency, linked to mutations in the gamma-
glutamyl carboxylase (GGCX; Vanakker et al., 2007) as well
as overlapping phenotypes due to co-segregating ABCC6 and
GGCX mutations (digenic inheritance) have been described
(Li et al., 2009a) or encountered for vitamin K epoxide reductase
complex, subunit 1 (VKORC1) genes (Li et al., 2009b). More
recently, mutations in another gene, ectonucleotide pyrophos-
phatase/phosphodiesterase 1 (ENPP1), associated with the soft
tissue mineralization disease generalized arterial calcification
of infancy, were shown to be associated with a PXE pheno-
type, difficult to distinguish clinically from classic ABCC6-
related PXE (Nitschke et al., 2012). In case of the acquired
forms of PXE, associated with e.g., haemoglobinopathies and
which shows similar clinical manifestations, no underlying
genetic susceptibility has been identified yet (Baccarani-Contri
et al., 2001; Hamlin et al., 2003).
Although fully penetrant, PXE is rarely present at birth and
an accurate diagnosis can often only be made several years
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after birth when ocular complications such as subretinal
neovascularization and hemorrhaging suddenly develop. In
addition, the considerable intra- and interfamilial hetero-
geneity in clinical severity as well as the lack of reliable
phenotype–genotype correlations pose a diagnostic challenge,
particularly in young, mildly affected patients. The variability
in clinical severity suggests the involvement of modifier genes;
recently, it was suggested that variants in the vascular
endothelial growth factor A gene were associated with a more
severe PXE retinopathy (Hendig et al., 2013). It can be
anticipated that, in the near future, other disease-modifying
genes will be described.
The challenge to achieve a clinical diagnosis of PXE
especially at younger age, combined with the genetic hetero-
geneity, stresses the importance of a molecular diagnosis.
Sanger sequencing (SS) is the current golden standard for
the detection of pathogenic variants (Tucker et al., 2009).
However, it is well known that this approach is labor
intensive, expensive, and time consuming, especially when
large genes need to be analyzed (Vanakker and De Paepe,
2013). In PXE, the reported mutation detection rates obtained
by SS are variable, ranging from 66% to 80–90%, probably
reflecting the size and molecular variability of the cohorts
examined (Pfendner et al., 2007; Hendig et al., 2013).
Because larger insertions or deletions can be missed by
direct sequencing, multiplex ligation-dependent probe
amplification (MLPA) analysis to detect larger deletions/
insertions is highly recommended (Costrop et al., 2010). The
recent introduction of the next-generation sequencing (NGS)
technology allows to perform a more efficient and cost-
effective screening, particularly for disorders with several
genes involved (Diamandis, 2009). Targeted enrichment of
specific genes of interest or whole-exome sequencing (WES),
sequencing all 20,805 coding genes in a single workflow, is
now becoming available to efficiently diagnose such
heterogeneous disorders.
In this study, we evaluated the use of WES as an efficient
diagnostic tool in 16 clinically confirmed PXE patients. The




The clinical characteristics of the PXE patients in this study are
summarized in Table 1. All patients presented the typical skin
and eye manifestations. The occurrence of cardiovascular
disease was variable, which is a common observation in
PXE. Only one patient suffered a gastrointestinal bleeding,
whereas none had coagulation problems (abnormalities of the
vitamin K–dependent coagulation factors II, VII, IX, and X).
WES analysis
First, the quality of the exome capturing and sequencing in
terms of the number of mapped reads, the coverage of the
targeted exons, and the amount of detected single-nucleotide
variants for all 16 patients were evaluated. On average 90% of
the raw reads mapped on the human hg19 reference genome.
We obtained a mean sequencing depth of 12 to 53 on
the targeted exome bases across the samples. Averaging all
samples, the mean depth on the targeted bases was 37x.
Approximately, 98% of the targeted exome bases were
covered across the samples. In relationship to the PXE
phenotype, the quality of the coding regions of the ABCC6,
GGCX, ENPP1, and VKORC1 genes was investigated in more
Table 1. Overview of phenotypic characterization of 16 patients
Patient Age (yrs) Sex Skin Eyes Cardiovascular GI hemorrhage Coagulation
1 35 M 1 1 1  
2 54 F 2 2 2  
3 33 M 1 1 1  
4 56 M 1 2 1  
5 49 F 2 2 1  
6 52 M 2 2 2 þ 
7 24 F 1 1 2  
8 63 F 2 2 2  
9 40 F 2 2 2  
10 61 F 2 2 1  
11 59 M 1 2 1  
12 35 F 1 1–2 1  
13 28 F 1 2 2  
14 34 M 1 2 2  
15 48 M 1 1 1  
16 43 F 1 1 1  
GI, gastrointestinal. Coagulation: deficiency of the vitamin K–dependent coagulation factors (factor II, VII, IX, and X).
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detail. For all samples the overall sequencing depth was
within the expected range (X97%,), except for patients 1
and 2 who revealed low quality data (Supplementary Tables
S1—S8 online).
In order to identify the disease-causing mutations in all four
genes, we analyzed all the exons that were 100% covered
with X1 and X5 reads (Figures 1 and 2) and found that 93,
84, 84, and 33% of the exons for ABCC6, GGCX, ENPP1, and
VKORC1, respectively, met this criteria for the overall sequen-
cing depth ofX5 reads (Figure 2). Our further strategy was to
investigate all exons with a depth lower compared with 20 by
SS. Previously, we demonstrated that variants with a coverage
o20 might be missed in 0.1% of the cases (Leeneer et al.,
2011; Figure 3 and Supplementary Tables S5—S8 online). The
latter analysis was performed for patients with only a single
mutation (Table 2). For patients 1 and 2, coverage was poor
for all four genes, which are in correlation with the poor
overall sequencing depth of their exomes.
Variants detected by exome sequencing
Exome sequencing of 16 patients revealed 30 mutant alleles
in the ABCC6 gene, which results in an overall mutation
detection rate of 93.75% (30/32). We did not take into
account the occurrence of a third mutation when determining
the mutation detection rate. Of these, five homozygous (P2, 4,
6, 9, 15), nine compound heterozygous (P1, 3, 7, 8, 10, 11,
12, 13, and 14), and two (P5 and 16) heterozygous mutations
were identified (Table 2). In one patient (P2) homozygous
deletion of exons 23 and 24 in ABCC6 was detected. In total,
six mutations–– four amino acid substitutions, a 5 bp exonic
deletion, and one intronic deletion–were previously unre-
ported in the ABCC6 gene. The pathological nature of these
previously unreported mutations was considered because the
variants were not or very rarely present in dbSNP131 or in the
1,000 genomes database. In addition, all these previously
unreported mutations were located in highly conserved
regions (high Polyphen score) and could also be predicted
by SIFT (Sorting Intolerant From Tolerant), Polyphen, and
Mutation taster, suggesting their pathogenic nature. One
patient (P7) shows a compound heterozygous ABCC6 muta-
tion in combination with a missense mutation in the GGCX
gene (Table 2). No mutations were found in the ENPP1 or
VKORC1 gene in this cohort. In addition, exome sequencing
resulted in 24 distinct exonic single-nucleotide polymorph-
isms (SNPs), 11 distinct SNPs in the intronic boundary, and
one SNP in the 30 UTR region in the four genes
(Supplementary Table S9 online). Most of these SNPs have a
minor allele frequency higher than 1% and are therefore not
considered as disease causing. Four of these SNPs have a
minor allele frequency o1% (Supplementary Table S10
online) and are difficult to exclude from the list of disease-
causing variants. However, splice prediction programs did not
reveal evidence for the presence of a splice site mutation of
these rare SNPs.
Confirmation by SS and MLPA and analyzing the exons with
insufficient reads
Mutations identified by WES could all be confirmed by SS. No
additional mutation in all exons with a sequence depth
coverage o20 for the two patients (P5, P16) with only one
ABCC6 mutation was detected by SS (Table 2). In addition,
MLPA analysis of these 2 patients for the ABCC6 gene
revealed no deletion or insertion. In order to verify the missing
allele, which is responsible for the PXE phenotype in the
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Figure 3. Percentage (%) of exons covered in four genes using X5 and X20
depth as a filter.
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was performed. We used two approaches: first, we looked at
whether homozygous or compound heterozygous mutations
could be found in genes other than ABCC6, GGCX, ENPP1,
and VKORC1. Supplementary Table S11 online summarizes
the three homozygous variants, which were considered as
possibly damaging and/or deleterious by in silico analysis.
However, none of these candidate genes could be confidently
linked with the pathomechanism of PXE. Using the same
filtering criteria, no compound heterozygous variants could be
retained. In a second approach, we looked at whether there
could be a digenic inheritance present in P5 and P16. We
therefore analyzed the heterozygous variants in the respective
exome data sets. Nearly 1,500 variants (including missense,
nonsense, frame-shift, in-frame indel, stop codon, splice
donor/acceptor) were obtained, which were limited by using
filtering criteria based on a population frequencyp1% and in
silico analysis (variants designated as deleterious or probably
damaging). This resulted in 17 missense variants (no other
variant types fulfilled the filtering criteria) in 13 candidate
genes, three of which overlapped in the two patients
(Supplementary Table S12 online). We further looked into
the function of these 13 genes and any relation with the
pathomechanisms of PXE. No indisputable functional associa-
tions could be delineated, particularly for those three shared
by both patients. At this point it remains difficult to make
definite conclusions on the basis of the available data of these
two patients. For both approaches, it will be necessary to
evaluate a larger cohort of patients with incomplete genotypes
using NGS to further evaluate these potential candidate genes
and/or identify novel ones; this is, however, beyond the scope
of this paper.
To rule out a whole exon deletion on one allele for the
p.(R518Q) mutation in ABCC6, MLPA was also performed for
patients P1 (with 3 ABCC6 mutation), which revealed no
additional deletion. Unfortunately, no MLPA analysis is avail-
able for the three other genes (ENPP1, GGCX, and ENPP1).
DISCUSSION
In this study, we applied WES in combination with SS as an
efficient molecular tool for the molecular diagnosis of PXE.
Sixteen patients with a clear PXE phenotype were investigated
for mutations in the ABCC6, GGCX, ENPP1, and VKORC1
genes, which revealed an overall mutation yield rate of
93.75%. With the applied degree of coverage (X5), WES
was able to detect all the mutations in the four genes. As
mentioned earlier, consideration of sequence depth coverage
of X5 as a filter implicates a 5% risk of missing heterozygous
mutations. We therefore considered, in a second step,
sequence depth coverage of X20 as a filter to achieve a
mutation detection rate ofB100% for those patients with only
one mutation and performed SS for those exons; however, no
additional mutations were identified in the four genes.
Table 2. List of mutations found by WES and SS
Gene Nucleotide change Protein change Patient ID Hom/Het WES SS Known/PUR Reference
ABCC6 c.C118T p.(P40S) P10 Het O O PUR
ABCC6 c.998þ2 998þ 3del TG P8 Het O O PUR
ABCC6 c.T1484A p.(L495H) P7 Het O O Known Miksch et al., 2005
ABCC6 c.G1553A p.(R518Q) P11 Hom O O Known Uitto et al., 2001
ABCC6 c.G1553A p.(R518Q) P12, P13, P14 Het O O Known Uitto et al., 2001
ABCC6 c.G2263A p.(G755R) P11 Het O O Known Pfendner et al., 2007
ABCC6 c.G2294A p.(R765Q) P3 Het O O Known Le Saux et al., 2001
ABCC6 del2860_2865 P12, P13,14 Het O O PUR
ABCC6 c.T2911C p.(W971R) P11 Het O O PUR
ABCC6 Ex23_24del P2 Hom O O Known Ringpfeil et al., 2001
ABCC6 c.T3032C p.(L1011P) P9 Hom O O PUR
ABCC6 c.C3190T p.(A1064T) P7 Het O O Known Miksch et al., 2005
ABCC6 c.G3413A p.(R1138Q) P11 Het O O Known Le Saux O, 2011
ABCC6 c.C3421T p.(R1141X) P4 Hom O O Known Bergen et al., 2000
ABCC6 c.C3421T p.(R1141X) P52, P8, P162 Het O O Known Bergen et al., 2000
ABCC6 c.C3490T p.(R1164X) P6, P15 Hom O O Known Struk et al., 2000
ABCC6 c.G4198A p.(E1400K) P10 Het O O Known Chassaing et al., 2004
ABCC6 c.C4216A p.(Q1406K) P3 Het O O PUR
GGCX c.C1321T p.(R441C) P7 Het O O PUR
Het, heterozygous; Hom, homozygous; PUR, previously unreported; SS, Sanger sequencing; WES, whole-exome sequencing.
1Patient with three mutations in ABCC6.
2Patients with a single mutation in ABCC6.
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In this cohort, 14 patients with homozygous or compound
heterozygous mutations were identified. Two patients present
an interesting genotype. Patient P1 carries three known
disease-causing mutations in ABCC6, a phenomenon that
has been described before by Pfendner et al. (2007), who
identified two subjects with three ABCC6 mutations.
However, no remarkable phenotypic differences were found
in these patients compared with the other PXE patients. In two
patients only a single ABCC6 mutation was detected. In
autosomal recessive diseases, the heterozygous state is most
often indistinguishable from the healthy state. However, a
partial PXE phenotype has been reported in some
heterozygous carriers (Martin et al., 2008). In some of these,
the p.(R1141X) mutation has been correlated with the
presence of coronary artery disease (Trip et al., 2002; Sherer
et al., 2001). In our cohort, two heterozygous patients, P5 and
P16, carry the p.(R1141X) mutation (Table 2). Although these
patients present occlusive vessel disease, the presence of
ocular and skin manifestations rather suggests that a second
mutation has been missed, owing to limitations of the current
technology, in the regions of the ABCC6 gene, which were not
analyzed––the 30 and 50 UTR, deep intronic sequences or
promotor region––or in another gene. Further detailed exam-
ination of the complete exome of patient P5 and P16 did not
reveal obvious mutations in other genes. In patient P7, we
observed compound heterozygosity for two ABCC6 missense
substitution (p.(L495H) and p.(A1064T)) mutations, as well as
a co-inherited missense substitution (p.(R441C)) mutation in
the GGCX gene. Vanakker et al. (2011) described a patient
with biallelic ABCC6 mutation and a gain-of-function SNP in
GGCX who displayed a phenotype partly reminiscent of both
PXE and the PXE-like disease with coagulation deficiency
(Vanakker et al., 2011). However, we remain cautious at this
moment on the role of the co-inherited GGCX mutation,
which may be acting as a disease modifier. Indeed, inter- as
well as intra-familial clinical variability in PXE suggests that
the contribution of factors other than ABCC6 variants also
affects the phenotypic features (Bacchelli et al., 1999;
Christen-Zach et al., 2006).
We showed that the WES approach in combination with SS
is an effective strategy in a polygenic disease that PXE has
become. It is well known that WES kits do not capture all
genes because of limitations inherent in the processes of
exome enrichment, library construction, and amplification. As
most exons of the four genes have a read depth of45, a range
by which all mutations were detected, the number of exons
that still need to be analyzed by SS is relatively low. Of
course, this is gene dependent and might not be applicable for
other sets of genes. We estimated that the reagent cost of
screening by the method presented here is cheaper compared
with the conventional methods. At the same time the analysis
is much less time consuming and more efficient, whereas
specificity and sensitivity are the same. The advantage of WES
compared with targeted enrichment of specific genes of
interest by array of PCR technology is that optimization is
independent of the genes involved as a standard procedure
can be used. The limited coverage compared with a targeted
enrichment approach is compensated by SS.
Another important advantage of WES is that it also provides
us the opportunity to screen for other PXE-related genes
including GGCX, ENPP1, and VKORC1 in a single workflow.
In addition, the availability of the complete exome sequence
allows us to investigate other genes not yet related to PXE at
this moment. Nevertheless, the combination with SS is
essential to fill the gaps with insufficient coverage but
also to adequately sequence the exons located in the pseudo-
genic region. The close sequence homology of the two
ABCC6 pseudogenes at the 5’ site hampers mutation detec-
tion, especially when a NGS approach is used, which is based
on an alignment of sequences to a reference sequence.
Nevertheless, we were able to identify the c.998þ
2_998þ3 delTG in exon 8, indicating that despite the high
similarity of the pseudogenic region, gene-specific mutations
are identified.
Besides identification of the causal genes, exome sequen-
cing in these patients will provide the opportunity to study the
involvement of modifier genes, such as GGCX, to explain the
variability in phenotypic expression between patients. The
efficacy of such a strategy, particularly when studying extreme
phenotypes, has previously been demonstrated in cystic
fibrosis (Emond et al., 2012).
In summary, we demonstrate that WES could be a rapid,
noninvasive, highly effective and economical method to
screen mutations in PXE and PXE-associated phenotypes, as
their molecular etiology becomes increasingly more complex,
whereas their clinical resemblance often makes it difficult to
predict the causal gene(s). Further, WES provides the oppor-
tunity to identify additional genes involved in PXE, both
disease-causing and disease-modifying. Although the use of
WES does currently not provide sufficient coverage of all
exons for comprehensive variant calling in a clinical diagnos-
tic setting, combined with SS and MLPA, it can be considered
as a reliable, efficient, and cost-effective approach to mole-
cular diagnostics of PXE.
MATERIALS AND METHODS
Approval and consent
Written, informed consent was obtained from all patients, and the
Declaration of Helsinki protocols were followed. This study was
approved by the local Ethical Committees (Ghent University Hospital
and University Hospital of Angers, France).
Phenotypical characterization
All patients in the present study were diagnosed with PXE based
on combination of skin pathology (the characteristic findings
of elastic fiber mineralization and fragmentation in the middermis
of lesional skin, using Verhoef-van Giesson and Von Kossa staining),
and fundus finding. The phenotype of the patients was summarized
as follows (Table 1): skin—S0: no macroscopic skin lesions, S1:
papular lesions, S2; plaques of papules; eyes—E0: no retinopathy,
E1: uncomplicated peau d’orange and/or angioid streaks, E2:
subretinal neovascularisation, hemorrhaging and vision loss;
cardiovascular—C0: no cardiovascular symptoms, C1: non-occlusive
vasculopathy, C2: occlusive vessel disease. Further, the occurrence
of gastrointestinal hemorrhaging and coagulation problems were
evaluated.
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Extraction of genomic DNA
Genomic DNA was extracted from the patient’s peripheral
whole blood using the High pure PCR Template Preparation Kit
(Roche Applied Sciences, Mannheim, Germany) or the genomic DNA
purification kit (Quick-gDNA MiniPrep-D3024, Zymo Research,
Freiburg, Germany), or the QIAmp DNA Mini Kit on the QIAcube
robot (Qiagen, Hilden, Germany) according to standard protocol.
Whole-Exome Sequencing
Exome capture was performed according to the manufacturer’s
protocol using the SeqCap EZ Human Exome Library v3.0 kit
(Roche/Nimblegen, Madison, WI). After ligation of the barcoded
Illumina (Eindhoven, The Netherlands) adapters, samples were
pooled per 2 before capturing. Consequently, 6 samples were
sequenced per Illumina HiSeq 2500 flow cell lane. On average
50E6 2x100bp paired end reads were sequenced per sample.
The CLC Genomics Workbench v6.5.1 (CLC Bio, Qiagen, Aarhus,
Denmark) software was used for read mapping against the human
genome reference sequence (NCBI, GRCh37.p5/hg19), duplicate
read removal, coverage analysis, and variant calling.
Variants were annotated with an in-house developed software
package, which makes use of the Ensembl API and Alamut Batch. To
reduce the number of variants, synonymous variants with no
predicted splice site disruption, variants with an allelic frequency
in the global 1,000G population 41%, and technical variants
(i.e., coverage o3 and observation in only one sequence direction)
were filtered out. The possible impact of variants on the protein
level and on the correct splicing was further assessed by
Alamut (http://www.interactive-biosoftware.com/software/alamut/
overview), Polyphen 2 (Adzhubei et al., 2010), and SIFTs (Kumar
et al., 2009) for conservation, physicochemical changes, and splice
site effects.
Initially, data analysis was restricted to variants in ABCC6, GGCX,
ENPP1, and VKORC1. In patients where only one mutation was
found the whole exome was analyzed.
SS
SS was performed to confirm the variants found with WES in the
ABCC6 and GGCX gene in all patients. Primers used for amplifying
fragments harboring individual variants were designed by Light-
Scanner primer design software (version: 1.0.R.84; Salt Lake City,
UT) and the sequences of these primers are listed in Supplementary
Table S13 online. Touch down PCR was used to amplify the genomic
fragments followed by SS on an ABI3130XL or ABI3730XL Genetic
Analyzer (Applied Biosystems, Foster City, CA).
MLPA
MLPA analysis of the ABCC6 gene was performed to evaluate the
presence of larger deletions or insertions by using commercially
available SALSA MLPA kit PO92-B3 (MRC-Holland, Amsterdam, The
Netherlands) and according to the manufacturer’s recommendations
(www.mlpa.com). The P092-B3 probemix contains one probe for each
exon of the ABCC6 gene, with the exception of exon 1, 3, 6, 16, 19,
20, 29, 31. A total of 100ng genomic DNA from each patient in total
5ml reaction volume was used. Fragments generated by MLPA were
detected by using an ABI3130XL or ABI3730XL capillary electrophor-
esis system (Applied Biosystems). Size, concentration, and quantifica-
tion of fragments were analyzed using Coffalyser (MRC-Holland).
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